Johns Hopkins的一项研究表明,无细胞DNA检测可以在症状发作前几周或几个月检测免疫疗法副作用,揭示早期器官损伤。 A Johns Hopkins study shows cell-free DNA testing can detect immunotherapy side effects weeks or months before symptoms, revealing early organ damage.

Johns Hopkins的一项研究发现,无细胞的DNA(cfDNA)检测可以检测出癌症免疫疗法中与免疫有关的不良事件(irAEs),在症状出现前的几周至几个月内发现,在6名拥有IRAE的病人中发现了多机体组织损伤——其中3名病人在236天前出现迹象——使用具体组织的DNA甲基化模式。 A Johns Hopkins study found that cell-free DNA (cfDNA) testing may detect immune-related adverse events (irAEs) from cancer immunotherapy weeks to months before symptoms appear, identifying multiorgan tissue damage in six patients with irAEs—three of whom showed signs up to 236 days earlier—using tissue-specific DNA methylation patterns. 在IRAE病人中,具体组织水平的cFDNA比受控制者高出六倍,这表明普遍器官损伤没有被标准方法所控制。 Levels of tissue-specific cfDNA were up to six times higher in irAE patients than in controls, suggesting widespread organ injury not captured by standard methods. 研究人员虽然受少量样本规模的限制,但认为CfCDNA测试可促成早期干预,提高治疗安全性,等待较大试验的验证。 While limited by small sample size, researchers believe cfDNA testing could enable earlier intervention and improve treatment safety, pending validation in larger trials.